Endometrial stromal sarcoma (ESS) is a rare malignant tumour of the endometrium, accounts for less than 1% of all
uterine malignancies. Routinely, it is diagnosed morphologically, supported by immunomarkers of CD10 and
vimentin. CD56 is used widely in neuroendocrine tumour. In our current practice, CD56 is not used to support the
diagnosis of ESS. We present a case of a postmenopausal lady with advanced ESS who had expression of CD56
upon immunohistochemical study